A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome.

Trial Profile

A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Quinagolide (Primary)
  • Indications Ovarian hyperstimulation syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 31 May 2012 Status changed from completed to recruiting as reported by European Clinical Trials Database.
    • 18 Sep 2009 Actual end date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Actual end date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top